CDC -Prevention of the development of sars-cov-2 (covid-19) disease by prophylactic administration of emtricitabine / tenofovir disoproxil and hydroxychloroquine in high-risk healthcare personnel: randomized, pl-controlled clinical trial
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: NATIONAL AIDS PLAN
- Phase: III
- Execution start: 06/04/2020
- End of execution: 06/04/2021
- PI: JUAN PASQUAU LIAÑO